Detalhe da pesquisa
1.
A wireless closed-loop system for optogenetic peripheral neuromodulation.
Nature
; 565(7739): 361-365, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30602791
2.
A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters.
Antimicrob Agents Chemother
; 60(12): 7407-7414, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27736766
3.
Opioids alter paw placement during walking, confounding assessment of analgesic efficacy in a postsurgical pain model in mice.
Pain Rep
; 7(5): e1035, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36034600
4.
Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity.
J Pharmacol Exp Ther
; 333(3): 707-16, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20228155
5.
Metabolic and Cardiac Adaptation to Chronic Pharmacologic Blockade of Facilitative Glucose Transport in Murine Dilated Cardiomyopathy and Myocardial Ischemia.
Sci Rep
; 8(1): 6475, 2018 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29691457
6.
Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat.
Diab Vasc Dis Res
; 4(2): 117-23, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17654445
7.
Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy.
Cardiovasc Endocrinol
; 1(4): 74-82, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23795310
8.
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
J Med Chem
; 53(16): 5970-8, 2010 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-20672820
9.
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
J Med Chem
; 53(16): 5979-6002, 2010 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-20672822
10.
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.
Hypertension
; 51(3): 742-8, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18250364